Familial hypercholesterolemia

Ochsner Journal

Volumn 14, Issue 4, 2014, Pages 669-672

  Pejic, Rade N ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Genetic diseases inborn; Hypercholesterolemia; Hyperlipoproteinemia type II

Indexed keywords

ALIROCUMAB; APOLIPOPROTEIN B; ATORVASTATIN; BILE ACID SEQUESTRANT; CHOLESTEROL; EVOLOCUMAB; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LOMITAPIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MIPOMERSEN; NICOTINIC ACID; PITAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

AEROBIC EXERCISE; APOB GENE; ARTICLE; AUTOSOMAL DOMINANT DISORDER; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL INTAKE; CLINICAL FEATURE; DIAGNOSTIC APPROACH ROUTE; DIETARY FIBER; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; FAMILIAL HYPERCHOLESTEROLEMIA; FRAMINGHAM RISK SCORE; GENE MUTATION; GENETIC PREDISPOSITION; GENETIC SCREENING; HUMAN; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; LIPOPROTEIN APHERESIS SYSTEM; LIVER TRANSPLANTATION; LOW FAT DIET; PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; SMOKING; TREATMENT INDICATION; TRIACYLGLYCEROL BLOOD LEVEL; XANTHELASMA; XANTHOMA;

EID: 84916884277     PISSN: 15245012     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Watts GF, Gidding S, Wierzbicki AS, et al. Integrated guidance on the care of familial hypercholesterolemia from the International FH foundation. J Clin Lipidol. 2014 Mar-Apr;8(2):148-172.
2. National Collaborating Centre for Primary Care. Identification and management of familial hypercholesterolaemia (FH). NICE Clinical Guidelines 71. London, England: Royal College of General Practitioners; 2008 Aug. http://www.ncbi.nlm.nih.gov/books?NBK53822/pdf/TOC.pdf. Accessed August 11, 2014.
3. Hopkins PN, Toth PP, Ballantyne CM, Rader DJ, National Lipid Association Expert Panel on Familial Hypercholesterolemia. Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011 Jun;5(3 Suppl):S9-S17.
4. LDLR [database]. University College London; 2007 [modified 2011 January]. http://www.ucl.ac.uk/ldlr/LOVDv.1.1.0/. Accessed May 31, 2014.
5. Hobbs HH, Brown MS, Goldstein JL. Molecular genetics of the LDL receptor gene in familial hypercholesterolaemia. Hum Mut. 1992;1(6):445-466.
6. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics. 2011 Dec;128 Suppl 5:S213-S256.
7. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001 May 16;285(19):2486-2497.
8. U.S. Preventive Services Task Force. Screening for Lipid Disorders in Adults: Recommendation Statement. June 2008. AHRQ Publication no.: 08-05114-EF-2. http://www. uspreventiveservicestaskforce.org/uspstf08/lipid/lipidrs.htm. Accessed August 11, 2014.
9. Lichtenstein AH, Ausman LM, Jalbert SM, et al. Efficacy of Therapeutic Lifestyle Change/Step 2 diet in moderately hypercholesterolemic middle-aged and elderly female and male subjects. J Lipid Res. 2002;43:264-273.
10. Bruckert E, Rosenbaum D. Lowering LDL cholesterol through diet: potential role in the statin era. Curr Opin Lipidol. 2011;22: 43-48.
11. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014 Jun 24; 129(25 Suppl 2):S1-S45.
12. Vuorio A, Kuoppala J, Kovanen PT, et al. Statins for children with familial hypercholesterolemia. Cochrane Database of Systematic Reviews 2014, Issue 7. Art. No.: CD006401. doi: 10.1002?14651858.CD006401.pub3.
13. Blom DJ, Hala T, Bolognese M, et al. A 52-week placebocontrolled trial of evolocumab in hyperlipidemia. N Engl J Med. 2014 May 8;370(19):1809-1819.
14. Roth EM, Taskinen MR, Ginsberg HN, et al. Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24 week double-blind, randomized Phase 3 trial. Int J Cardiol. doi:10.1016/j.ijcard.2014.06.049.